WO1999047515A1 - Derives d'arylpiperidine et utilisation de ceux-ci - Google Patents
Derives d'arylpiperidine et utilisation de ceux-ci Download PDFInfo
- Publication number
- WO1999047515A1 WO1999047515A1 PCT/JP1998/001180 JP9801180W WO9947515A1 WO 1999047515 A1 WO1999047515 A1 WO 1999047515A1 JP 9801180 W JP9801180 W JP 9801180W WO 9947515 A1 WO9947515 A1 WO 9947515A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- atom
- formula
- carbon atoms
- pharmaceutically acceptable
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 15
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 32
- 125000004432 carbon atom Chemical group C* 0.000 claims description 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 229960003638 dopamine Drugs 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 6
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 claims description 6
- 239000002464 receptor antagonist Substances 0.000 claims description 6
- 229940044551 receptor antagonist Drugs 0.000 claims description 6
- 229910052751 metal Chemical class 0.000 claims description 5
- 239000002184 metal Chemical class 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 125000005245 nitryl group Chemical group [N+](=O)([O-])* 0.000 claims description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 abstract description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 88
- -1 3,4-dimethylphenyl Chemical group 0.000 description 56
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 54
- 150000001875 compounds Chemical class 0.000 description 54
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 52
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 30
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 28
- 239000002904 solvent Substances 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 239000012442 inert solvent Substances 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 108020003175 receptors Proteins 0.000 description 20
- 102000005962 receptors Human genes 0.000 description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- 150000001298 alcohols Chemical class 0.000 description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 12
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 12
- 238000009739 binding Methods 0.000 description 12
- 150000002170 ethers Chemical class 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- 230000027455 binding Effects 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 229930195733 hydrocarbon Natural products 0.000 description 8
- 150000002430 hydrocarbons Chemical class 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000000704 physical effect Effects 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 208000018300 basal ganglia disease Diseases 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 7
- 230000002140 halogenating effect Effects 0.000 description 7
- 150000007529 inorganic bases Chemical class 0.000 description 7
- 239000012046 mixed solvent Substances 0.000 description 7
- 201000000980 schizophrenia Diseases 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 229910052794 bromium Inorganic materials 0.000 description 6
- 229960004170 clozapine Drugs 0.000 description 6
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 6
- 238000003818 flash chromatography Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000001632 sodium acetate Substances 0.000 description 6
- 235000017281 sodium acetate Nutrition 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000002274 desiccant Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 150000003053 piperidines Chemical class 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- WAOQONBSWFLFPE-VIFPVBQESA-N 3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(O)C(Cl)=CC(Cl)=C1OC WAOQONBSWFLFPE-VIFPVBQESA-N 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- PHENPABYBHPABM-UHFFFAOYSA-N acetic acid;octane Chemical compound CC(O)=O.CCCCCCCC PHENPABYBHPABM-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 4
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 4
- OFHAGSNEHHNRSV-UHFFFAOYSA-N 1-benzothiophene;hydrochloride Chemical compound Cl.C1=CC=C2SC=CC2=C1 OFHAGSNEHHNRSV-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000012024 dehydrating agents Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 150000002896 organic halogen compounds Chemical class 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- 125000005999 2-bromoethyl group Chemical group 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 2
- BBHHDHNDHFUPST-UHFFFAOYSA-N 5-(2-chloroethyl)-4-(4-fluorophenyl)-2-methylsulfanyl-1h-imidazole Chemical compound N1C(SC)=NC(CCCl)=C1C1=CC=C(F)C=C1 BBHHDHNDHFUPST-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000027776 Extrapyramidal disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 150000002081 enamines Chemical class 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 2
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 150000003556 thioamides Chemical class 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 description 1
- QHDXPJMOWRLLRV-UHFFFAOYSA-N 1-(4-fluorophenyl)butan-1-one Chemical compound CCCC(=O)C1=CC=C(F)C=C1 QHDXPJMOWRLLRV-UHFFFAOYSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- KYUGCPXEZSVXBJ-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-thiazole hydrochloride Chemical compound Cl.FC1=CC=C(C=C1)C=1SC=CN1 KYUGCPXEZSVXBJ-UHFFFAOYSA-N 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000001331 3-methylbutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- CZWWCTHQXBMHDA-UHFFFAOYSA-N 3h-1,3-thiazol-2-one Chemical class OC1=NC=CS1 CZWWCTHQXBMHDA-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OBHMTXKJVROLQU-UHFFFAOYSA-N 4-(4-fluorophenyl)-1,3-thiazole Chemical compound C1=CC(F)=CC=C1C1=CSC=N1 OBHMTXKJVROLQU-UHFFFAOYSA-N 0.000 description 1
- MZRDNBCYGJUJLM-UHFFFAOYSA-N 4-(6-fluoro-1-benzothiophen-3-yl)piperidine Chemical compound C=1SC2=CC(F)=CC=C2C=1C1CCNCC1 MZRDNBCYGJUJLM-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- HXAOUYGZEOZTJO-UHFFFAOYSA-N 4-chloro-1-(4-fluorophenyl)butan-1-one Chemical compound FC1=CC=C(C(=O)CCCCl)C=C1 HXAOUYGZEOZTJO-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- ASAMCDOTLOUAAR-UHFFFAOYSA-N 5-ethyl-1,3-thiazole Chemical compound CCC1=CN=CS1 ASAMCDOTLOUAAR-UHFFFAOYSA-N 0.000 description 1
- IAWIFBMBSZRKGZ-UHFFFAOYSA-N 6-fluoro-1-benzothiophene Chemical compound FC1=CC=C2C=CSC2=C1 IAWIFBMBSZRKGZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940095564 anhydrous calcium sulfate Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- QNEFNFIKZWUAEQ-UHFFFAOYSA-N carbonic acid;potassium Chemical compound [K].OC(O)=O QNEFNFIKZWUAEQ-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000442 dopamine 2 receptor blocking agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 1
- YMBMCMOZIGSBOA-UHFFFAOYSA-N ethyl 2-amino-2-sulfanylideneacetate Chemical compound CCOC(=O)C(N)=S YMBMCMOZIGSBOA-UHFFFAOYSA-N 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000003196 psychodysleptic agent Substances 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 108010092215 spiroperidol receptor Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000007979 thiazole derivatives Chemical class 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to arylbiperidine derivatives having an antipsychotic effect.
- Antipsychotics are also used to treat schizophrenia and cerebrovascular disorders and problematic behaviors in senile dementia (aggression, mental excitement, wandering, delirium, etc.). Nevertheless, the conventional de one dopamine 0 2 receptor antagonist is an anti-psychotic drug, extrapyramidal disorders has become a strong, large problem is a side effect.
- dopamine D 4 receptor antagonists unlike dopamine D 2 receptor antagonists, are very likely to be new schizophrenia treatments without the side effect of extrapyramidal disorders (Nature, 350_, 610 614 (1991); Nature, 358, 109 (1992); Nature, 365. 393 (1993); Nature, 365. 441-445 (1993)).
- Clozapine is clozapine. Affinity for clozapine de one Pas Min D 4 receptor have been reported to be higher than the affinity for de one dopamine D 2 receptor (Nature, 350, 610 ⁇ 614 (1991 )). Furthermore, in clinical trials of clozapine, unlike dopamine D 2 receptor antagonist, is effective in schizophrenia and negative symptoms of drug resistance has been reported to be less extrapyramidal disorder (Arch. Gen. Psych , 45, 789-796 (1988)). Clozapine, a clozapine, has a blood disorder called agranulocytosis and has been reported to have died (Summary and Clinical Data. Sandoz, Canada Inc. (1990)), which is a major drawback. ing.
- dopamine D 4 receptor antagonists without such side effects, a high usefulness as therapeutic agents, such as extremely low schizophrenia may cause extrapyramidal disorders No.
- An object of the present invention is to provide a dopamine 1) 4 receptor antagonistic compound having an antipsychotic effect without causing extrapyramidal disorders.
- the present inventors have conducted intensive studies on arylpyperidine derivatives, and as a result, have found a novel arylpyridine derivative exhibiting high affinity for a dopamine receptor, and have completed the present invention.
- the present invention provides a compound of the formula (I)
- D represents a carbon atom or a nitrogen atom
- E represents a CH group or a nitrogen atom
- G represents an oxygen atom, a zeo atom, a nitrogen atom or an NH group
- Y 1 represents a hydrogen atom or a halogen atom.
- ⁇ represents an integer of 1 to 4,
- R 1 has the formula (i):
- R 2 is a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, an amino group, a monoalkylamino group having 1 to 5 carbon atoms, a hydroxyl group, an alkoxycarbonyl group having 2 to 6 carbon atoms, Represents a rubamoyl group, a carboxyl group or a metal salt of a carboxyl group, and Ar represents a substituted or unsubstituted phenyl group or a phenyl group.
- R 3 represents an alkyl group having 1 to 5 carbon atoms
- X ′ and X 2 are different from each other and represent a nitrogen atom or an NH group
- Ar is a substituted or unsubstituted phenyl group or a phenyl group. Represents a nitryl group.
- X ′ and X 2 are the same as described above, and Ar represents a substituted or unsubstituted phenyl group or a phenyl group.
- R 4 represents a hydrogen atom, a mercapto group, an alkylthio group having 1 to 5 carbon atoms, and Ar represents a substituted or unsubstituted fuunyl group or a chenyl group.
- the substituted phenyl group is one or two substituents arbitrarily selected from a halogen atom, an alkyl group having 1 to 5 carbon atoms, an alkoxy group having 1 to 5 carbon atoms and a trifluoromethyl group.
- a phenyl group having a group for example, 2-fluorophenyl group, 3-fluorophenyl group, 4-fluorophenyl group, 4-chlorophenyl group.
- Phenyl, 4-bromophenyl, 3,4-dichlorophenyl, 4-methylphenyl, 3,4-dimethylphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 2-trifluoro Examples include an orthomethylphenyl group, a 3-trifluoromethylphenyl group, and a 4-trifluoromethylphenyl group.
- a halogen atom is a fluorine, chlorine, bromine or iodine atom.
- An alkyl group having 1 to 5 carbon atoms is a linear, branched or cyclic alkyl group, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl. Group, t-butyl group, cyclopropylmethyl group, pentyl group, isopentyl group and the like.
- the alkoxy group having 1 to 5 carbon atoms means a linear or branched alkoxy group, such as methoxy, ethoxy, methoxy, isopropoxy, butoxy, isobutoxy, t-butoxy group, pentoxy group, 3-methylbutoxy group and the like.
- Examples of the monoalkylamino group having 1 to 5 carbon atoms include a methylamino group, an ethylamino group, a propylamino group, and an isopropylamino group.
- alkylthio group having 1 to 5 carbon atoms examples include a methylthio group, an ethylthio group, a propylthio group, an isopropylthio group, a butylthio group and an isobutylthio group.
- the alkoxycarbonyl group having 2 to 6 carbon atoms includes, for example, a methoxycarbonyl group, an ethoxyquincarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group and the like.
- the pharmaceutically acceptable salts in the present invention include, for example, salts with mineral acids such as sulfuric acid, hydrochloric acid and phosphoric acid, acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, trifluoroacetic acid, methanesulfone Salts with organic acids such as acid, pamoic acid, decanoic acid and enanthic acid.
- mineral acids such as sulfuric acid, hydrochloric acid and phosphoric acid
- acetic acid oxalic acid
- lactic acid tartaric acid
- fumaric acid maleic acid
- trifluoroacetic acid methanesulfone Salts with organic acids such as acid, pamoic acid, decanoic acid and enanthic acid.
- the arylbiperidine derivative represented by the general formula (I) wherein R 1 is represented by the general formula (ii) or (iii) has a tautomer in its chemical structure. Also includes these tautomers.
- Preferred compounds in the present invention are represented by the following formula ( ⁇ ):
- Y 1 has the same meaning as described above, Y 2 represents a hydrogen atom or a halogen atom, J represents an oxygen atom, a zeo atom or an NH group, and R 5 is an alkyl having 1 to 5 carbon atoms. Group, amino group or sorbamoyl group.
- the compound of the formula (I) can be produced by the following method.
- R 6 is a hydrogen atom
- R 6 represents an alkyl group having 1 to 5 carbon atoms, an amino group, a monoalkylamino group having 1 to 5 carbon atoms
- R 7 and R 8 together with an adjacent nitrogen atom represent a pyrrolidino group, a piperidino group, a morpholino group
- N — Represents a methylbiperazino group
- Z represents a chlorine atom, bromine atom or iodine atom
- M ′ represents, for example, sodium, potassium, NH 4
- M 2 represents an alkali metal ion such as sodium, potassium, lithium, calcium, alkali Indicates an earth metal ion or a hydrogen atom.
- a thiourea derivative or a thioamide derivative represented by the formula (2) After halogenating the ketone body (1) with a halogenating agent in an inert solvent, react it with a thiourea derivative or a thioamide derivative represented by the formula (2) in an inert solvent in the presence or absence of a dehydrating agent.
- the compound (4) is obtained by reacting a urea derivative or amide derivative represented by the formula (3) with a sulfurizing agent.
- the compound (6) of the present invention can be obtained by reacting the compound (4) with a piperidine derivative represented by the formula (5) in an inert solvent in the presence of a base.
- the inert solvent in this reaction includes, for example, organic carboxylic acids such as acetic acid, organic halogen compounds such as chloroform, carbon tetrachloride, alcohols such as ethanol and isopropanol, ethers such as tetrahydrofuran and dioxane, benzene and toluene. And the like, ketone compounds such as acetone and methyl ethyl ketone, N, N-dimethylformamide, acetonitrile, water or a mixed solvent thereof.
- the halogenating agent is, for example, chlorine, bromine, iodine, sulfuryl chloride or the like.
- Examples of the dehydrating agent include molecular sieves such as Molecular Sieves 3A and Molecular Sieves 4A, inorganic salts such as anhydrous magnesium sulfate, anhydrous calcium sulfate, and anhydrous calcium chloride, and phosphorus pentoxide.
- Examples of the sulfurizing agent include phosphorus pentasulfide and Lawson's reagent.
- the base includes, for example, organic amines such as triethylamine, diisopropylethylamine, and pyridine; alcoholates such as sodium ethoxide; alkali metal amides such as sodium amide; sodium hydrogencarbonate; and sodium carbonate.
- Inorganic bases such as potassium carbonate, sodium hydroxide and sodium hydride; and organic acid salts such as sodium acetate.
- the ketone compound (1) is halogenated with a halogenating agent in the same manner as in Reaction Scheme 1, reacted with thiocyanate (7) in an inert solvent, and then treated with an acid to obtain a 2-hydroxythiazole derivative (8).
- a halogenating agent in the same manner as in Reaction Scheme 1, reacted with thiocyanate (7) in an inert solvent, and then treated with an acid to obtain a 2-hydroxythiazole derivative (8).
- the inert solvent includes, for example, organic carboxylic acids such as acetic acid, organic halogen compounds such as carbon tetrachloride and chloroform, ethanol, isopropanol, and the like.
- organic carboxylic acids such as acetic acid
- organic halogen compounds such as carbon tetrachloride and chloroform
- ethanol isopropanol
- alcohols ethers such as getyl ether and tetrahydrofuran
- hydrocarbons such as toluene, N, N-dimethylformamide, acetonitrile, water, or a mixed solvent thereof.
- Acid treatment refers to, for example, using acids such as hydrochloric acid, sulfuric acid, acetic acid, trifluoroacetic acid, methanesulfonic acid, and tosylic acid alone or as a mixture, in alcohols such as methanol, ethanol, ethers such as dioxane, or in water. Is to react.
- the compound (9) of the present invention can be obtained by reacting the compound (8) with the piperidine derivative (5) in an inert solvent in the presence of a base.
- the inert solvent in this reaction includes, for example, alcohols such as ethanol and isopropanol, ethers such as tetrahydrofuran and dioxane, hydrocarbons such as benzene and toluene, ketone compounds such as acetone and methyl ethyl ketone, and N , N-dimethylformamide, acetonitrile, water or a mixed solvent thereof.
- the bases include, for example, organic amines such as triethylamine, disopropylethylamine, pyridin, alcohols such as sodium ethoxide, alkali metal amides such as sodium amide, and sodium hydrogen carbonate.
- Inorganic bases such as sodium carbonate, potassium carbonate, sodium hydroxide, and sodium hydride; and organic acid salts such as sodium acetate.
- the ketone compound (1) is halogenated with a halogenating agent in the same manner as in Reaction Scheme 1, and then reacted with a thioamide derivative (10) in an inert solvent in the presence or absence of a dehydrating agent to obtain a thiazole derivative (1). 1) can be obtained. Furthermore, the compound (11) of the present invention can be obtained by reacting the compound (11) with the piperidine derivative (5) in an inert solvent in the presence of a base.
- the inert solvent in this reaction includes, for example, alcohols such as ethanol and isopropanol, ethers such as tetrahydrofuran and dioxane, hydrocarbons such as benzene and toluene, and ketone compounds such as acetone and methyl ethyl ketone. , N, N-dimethylformamide, acetonitrile, water or a mixed solvent thereof.
- Bases include, for example, organic amines such as triethylamine, diisopropylethylamine, pyridin, alcohols such as sodium ethoxide, metal amides such as sodium amide, and hydrogen carbonate.
- Inorganic bases such as sodium, sodium carbonate, potassium carbonate, sodium hydroxide, sodium hydride, sodium acetate Five
- the compound (13) can be converted to the compound (13) of the present invention by treating the compound (12) with ammonia in an inert solvent.
- inert solvent in this reaction examples include ethers such as getyl ether, tetrahydrofuran, and dioxane; alcohols such as methanol and ethanol; acetonitrile; and water.
- the compound (14) of the present invention can be obtained by hydrolyzing the ester group of the compound (12) in an inert solvent in the presence of a base or an acid.
- the inert solvent in this reaction includes, for example, ethers such as diethyl ether, tetrahydrofuran, and dioxane; alcohols such as methanol and ethanol; ketones such as acetone; organic carboxylic acids such as acetic acid; Examples include dimethylformamide and water.
- the base include inorganic bases such as sodium hydroxide, potassium hydroxide, lithium hydroxide, 7K barium oxide, calcium hydroxide, and sodium carbonate.
- the acid include acids such as hydrochloric acid, hydrobromic acid, and sulfuric acid. Inorganic acids, organic acids such as trifluoroacetic acid, formic acid, tosylic acid, and methylsulfonic acid. (Reaction formula 5) H
- the ketone compound (1) is halogenated with a halogenating agent in the same manner as in Reaction Scheme 1, and reacted with an S-alkylisothiourea derivative (15) in an inert solvent in the presence of a base to give an imidazole derivative (1). 1 6) can be obtained. Further, the compound (17) of the present invention can also be obtained by reacting the compound (16) with the piperidine derivative (5) in an inert solvent in the presence of a base.
- Examples of the inert solvent in this reaction include alcohols such as ethanol and isopropanol, ethers such as tetrahydrofuran and dioxane, hydrocarbons such as benzene and toluene, ketone compounds such as acetone and methylethylketone, and N , N-dimethylformamide, acetonitrile, water or a mixed solvent thereof.
- the base includes, for example, organic amines such as triethylamine, diisopropylethylamine, and pyridin; alcohols such as sodium ethoxide; metal amides such as sodium dimamide; sodium hydrogen carbonate; and carbonate.
- Inorganic bases such as sodium, potassium carbonate, sodium hydroxide and sodium hydride; and organic acid salts such as sodium acetate. (Reaction formula 6)
- Amino ketone (18) can be obtained by reacting ketone (1) with piperidine derivative (5) in the presence or absence of a base in an inert solvent or without solvent. .
- a base is, for example, an organic amine such as triethylamine, diisopropylethylamine, or pyridine; an inorganic base such as sodium hydrogencarbonate, sodium carbonate, carbonated sodium carbonate, sodium hydroxide, or sodium hydride; Organic salts such as sodium acetate.
- Inert solvents include, for example, These include ethers such as furan and dioxane, hydrocarbons such as benzene and toluene, and alcohols such as ethanol.
- the enamine derivative (20) obtained by reacting the aminoketone (18) with N, N-dimethylformamide dialkyl acetal (19) in the presence of a cyclic amine in an inert solvent is converted to hydrazine.
- the compound (21) of the present invention can be obtained.
- Cyclic amino in this reaction refers to, for example, pyrrolidine, piperidine, morpholine, N-methylbiperazine, and the like.
- Inert solvents include, for example, ethers such as tetrahydrofuran and dioxane, hydrocarbons such as benzene and toluene, and acetonitrile. , N, N-dimethylformamide and the like.
- Examples of the solvent for the reaction with hydrazine include alcohols such as methanol, ethanol, and isopropanol; ethers such as getyl ether and tetrahydrofuran; hydrocarbons such as toluene; N, N-dimethylformamide; Examples include acetonitrile, water, or a mixed solvent thereof.
- the enamine derivative (20) is mixed with a mixture of formamide and ammonium formate (22), thiorea (23) or S-alkylisothiorea (14) in an inert solvent in the presence of a base, if necessary. By reacting, the compound of the present invention (24) can be obtained.
- a base is, for example, an organic amine such as triethylamine, disopropylethylamine, pyridine, or the like; an inorganic base such as sodium hydrogen carbonate, sodium carbonate, carbon dioxide, sodium hydroxide, sodium hydride, or the like. And organic acid salts such as sodium acetate.
- the inert solvent includes, for example, organic carboxylic acids such as acetic acid, organic halogen compounds such as carbon tetrachloride and chloroform, alcohols such as ethanol and isopropanol, ethers such as getyl ether and tetrahydrofuran, and toluene. And hydrocarbons such as N, N-dimethylformamide, acetate nitrile, water or a mixed solvent thereof.
- the compounds of the present invention while exhibiting excellent affinity for the dopamine D 4 receptor, the affinity for dopamine D 2 receptors is low, shows excellent separation properties. Therefore, the compound of the present invention is useful as an agent for preventing and treating diseases such as schizophrenia, cerebrovascular disorder and problematic behavior associated with senile dementia, and a drug not accompanied by an extrapyramidal disorder as a side effect.
- diseases such as schizophrenia, cerebrovascular disorder and problematic behavior associated with senile dementia, and a drug not accompanied by an extrapyramidal disorder as a side effect.
- the compound of the present invention is added with conventional bulking agents, binders, disintegrants, pH regulators, solubilizers and the like, and tablets, pills, capsules, granules are produced by conventional formulation techniques. Preparations, powders, solutions, emulsions, suspensions, injections and the like.
- the compound of the present invention can be orally or parenterally administered to an adult patient in one or several portions of 0.1 to 50018 days. This dose can be appropriately adjusted according to the type of disease, age, weight, and symptoms of the patient.
- Table A shows the structure and physical properties data of this compound and the compound obtained in the same manner.
- Table A shows the structure and physical property data of this compound.
- the residue was heated to reflux under stirring for 3 hours in a mixture of 140 ml of acetic acid, 40 ml of water and 15 ml of sulfuric acid. After concentrating the reaction solution under reduced pressure, the residue was poured into ice and extracted with ethyl acetate. The extract was washed with water, a saturated aqueous solution of sodium hydrogencarbonate, and saturated saline, dried over anhydrous sodium sulfate, and the desiccant was filtered off.
- reaction mixture was concentrated under reduced pressure, ethyl acetate was added to the residue, and the mixture was washed successively with a saturated aqueous solution of sodium hydrogen carbonate and a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate, filtered to remove the desiccant, and concentrated under reduced pressure. .
- Table A shows the structure and physical properties data of this compound and the compound obtained in the same manner.
- Table B shows the structure and physical properties data of this compound and the compound obtained in the same manner.
- Table B shows the structure and physical properties data of this compound and the compound obtained in the same manner.
- Table B shows the structure and physical properties data of this compound and the compound obtained in the same manner.
- Table C shows the structure and physical property data of this compound and the compound obtained in the same manner.
- thiophene obtained by the operation C.
- 0.4 g of ammonium formate (0.4 g) and 0.1 ml of water were added, and the mixture was heated and stirred at 180 ° C. for 1.5 hours.
- Human D 4 as a receptor preparation Using Chinese hamster ovary (CHO) cell membranes expressing the receptor.
- CHO Chinese hamster ovary
- the binding reaction using the [ 3 H] -labeled ligand was carried out by the following method described in Eur. J. Pharmacol., 233, 173 (1993).
- Human D 4 .2 receptor binding test Human D 4 2 receptors CHO cell membranes expressing the, the [3 H] spiperone (0. 5 nM) and test drug, 5 mM EDTA, 1. 5 mM calcium chloride, The reaction was carried out at 27 ° C. for 2 hours in 50 mM Tris-HCl buffer (pH 7.4) containing 5 mM potassium chloride and 12 OmM sodium chloride. After completion of the reaction, the solution was suction-filtered through a glass filter (GFZB), and the radioactivity of the filter paper was measured with a liquid scintillation spectrum meter.
- GFZB glass filter
- the binding when reacted in the presence of 10 ⁇ M haloperidol was defined as nonspecific binding of [ 3 H] spiperone, and the difference between total binding and nonspecific binding was defined as specific binding.
- the inhibition curve was obtained by reacting a constant concentration of [ 3 H] spiperone with a test drug of varying concentration under the above conditions, and from this inhibition curve, the concentration of the test drug that inhibited [ 3 H] spiperone binding by 50% ( IC 5 o) was determined and the results are shown in Table D.
- Rat striatal membrane was used as a receptor preparation.
- the binding reaction using the [ 3 H] -labeled ligand was performed by the following method described in o 1. Pharmacol., 43, 749 (1993).
- Rat striatum was homogenized with 50 mM Tris-HCl buffer (pH 7.4), centrifuged at 48,000 X g, and the precipitate was washed once with Tris-HCl buffer .
- the precipitate was suspended in 50 mM Tris-HCl buffer (pH 7.4) containing 120 mM sodium chloride, 5 mM potassium chloride, 2 mM calcium chloride, and 1 mM magnesium chloride, and used as a membrane sample.
- the compounds of the present invention while exhibiting excellent affinity for de one dopamine D 4 receptor, affinity for Dopami emissions D 2 receptors is low, shows excellent separation properties.
- the compound of the present invention is useful as an agent for preventing and treating diseases such as schizophrenia and cerebrovascular disorders and problematic behavior associated with senile dementia, and as a drug not having the side effect of extrapyramidal disorders. Useful.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020007010329A KR20010042001A (ko) | 1998-03-19 | 1998-03-19 | 아릴피페리딘 유도체 및 그의 용도 |
EP19980909760 EP1070715A4 (en) | 1998-03-19 | 1998-03-19 | ARYLPIPERIDINE AND THEIR USE |
PCT/JP1998/001180 WO1999047515A1 (fr) | 1998-03-19 | 1998-03-19 | Derives d'arylpiperidine et utilisation de ceux-ci |
CA002324550A CA2324550A1 (en) | 1998-03-19 | 1998-03-19 | Arylpiperidine derivatives and use thereof |
AU64196/98A AU747508B2 (en) | 1998-03-19 | 1998-03-19 | Arylpiperidine derivatives and use thereof |
CNB988139170A CN1166665C (zh) | 1998-03-19 | 1998-03-19 | 芳基哌啶衍生物及其用途 |
US09/646,080 US6407121B1 (en) | 1998-03-19 | 1998-03-19 | Arylpiperidine derivatives and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP1998/001180 WO1999047515A1 (fr) | 1998-03-19 | 1998-03-19 | Derives d'arylpiperidine et utilisation de ceux-ci |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/646,080 A-371-Of-International US6407121B1 (en) | 1998-03-19 | 1998-03-19 | Arylpiperidine derivatives and use thereof |
US10/120,408 Division US6806275B2 (en) | 2000-09-13 | 2002-04-12 | Arylpiperidine derivatives and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999047515A1 true WO1999047515A1 (fr) | 1999-09-23 |
Family
ID=14207827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/001180 WO1999047515A1 (fr) | 1998-03-19 | 1998-03-19 | Derives d'arylpiperidine et utilisation de ceux-ci |
Country Status (7)
Country | Link |
---|---|
US (1) | US6407121B1 (ja) |
EP (1) | EP1070715A4 (ja) |
KR (1) | KR20010042001A (ja) |
CN (1) | CN1166665C (ja) |
AU (1) | AU747508B2 (ja) |
CA (1) | CA2324550A1 (ja) |
WO (1) | WO1999047515A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1242072A1 (en) * | 1999-12-17 | 2002-09-25 | Bristol-Myers Squibb Company | Antipsychotic heterocycle compounds |
US6703383B2 (en) | 2000-09-11 | 2004-03-09 | Sepracor, Inc. | Antipsychotic sulfonamide-heterocycles, and methods of use thereof |
EP1598068A1 (en) * | 1999-12-17 | 2005-11-23 | Bristol-Myers Squibb Company | Antipsychotic heterocycle compounds |
CN100386323C (zh) * | 2006-02-27 | 2008-05-07 | 南京长澳医药科技有限公司 | 马来酸多潘立酮的合成方法 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9903544D0 (sv) * | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
GB2359078A (en) * | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
GB2359551A (en) * | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
GB0005642D0 (en) * | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
HUP0302473A2 (hu) * | 2000-05-18 | 2003-11-28 | Daiichi Pharmaceutical Co., Ltd. | Új benzotiofénszármazékok |
SE0003828D0 (sv) * | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
SE0101322D0 (sv) * | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
SE0102716D0 (sv) * | 2001-08-14 | 2001-08-14 | Astrazeneca Ab | Novel compounds |
GB0221828D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
GB0221829D0 (en) * | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
GB0328243D0 (en) * | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
CN101096363B (zh) * | 2006-06-27 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途 |
BR102012024778A2 (pt) * | 2012-09-28 | 2014-08-19 | Cristalia Prod Quimicos Farm | Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02240068A (ja) * | 1989-01-26 | 1990-09-25 | Ist Luso Farmaco Italia Spa | 中枢神経系に活性を有し、血圧降下活性を有するイミダゾール誘導体、それらの製造方法、ならびにそれらを含有する製薬組成物 |
JPH04352770A (ja) * | 1991-05-30 | 1992-12-07 | Taisho Pharmaceut Co Ltd | アミノアルキルチアゾール誘導体 |
JPH07291969A (ja) * | 1994-04-22 | 1995-11-07 | Merck Patent Gmbh | 3−インドリルピペリジン |
JPH08508030A (ja) * | 1993-03-18 | 1996-08-27 | メルク シヤープ エンド ドーム リミテツド | ベンゾイミダゾール誘導体 |
JPH08325257A (ja) * | 1995-05-31 | 1996-12-10 | Adir | 新規なピペラジン、ピペリジン及び1,2,5,6−テトラヒドロピリジン化合物、これらの製造方法及びこれらを含む医薬組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2349331A1 (fr) * | 1976-04-30 | 1977-11-25 | Roussel Uclaf | Nouveaux derives de 2,3 dihydro a/4-(3-indolyl) 1-piperidinyl/methyl 1,4-benzodioxin-2-methanol, un procede pour leur preparation et leur application comme medicaments |
GB8719167D0 (en) * | 1987-08-13 | 1987-09-23 | Glaxo Group Ltd | Chemical compounds |
NZ254113A (en) * | 1992-07-13 | 1995-08-28 | Janssen Pharmaceutica Nv | Fused piperidine derivatives and medicaments |
-
1998
- 1998-03-19 US US09/646,080 patent/US6407121B1/en not_active Expired - Fee Related
- 1998-03-19 WO PCT/JP1998/001180 patent/WO1999047515A1/ja not_active Application Discontinuation
- 1998-03-19 CA CA002324550A patent/CA2324550A1/en not_active Abandoned
- 1998-03-19 EP EP19980909760 patent/EP1070715A4/en not_active Withdrawn
- 1998-03-19 CN CNB988139170A patent/CN1166665C/zh not_active Expired - Fee Related
- 1998-03-19 AU AU64196/98A patent/AU747508B2/en not_active Ceased
- 1998-03-19 KR KR1020007010329A patent/KR20010042001A/ko not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02240068A (ja) * | 1989-01-26 | 1990-09-25 | Ist Luso Farmaco Italia Spa | 中枢神経系に活性を有し、血圧降下活性を有するイミダゾール誘導体、それらの製造方法、ならびにそれらを含有する製薬組成物 |
JPH04352770A (ja) * | 1991-05-30 | 1992-12-07 | Taisho Pharmaceut Co Ltd | アミノアルキルチアゾール誘導体 |
JPH08508030A (ja) * | 1993-03-18 | 1996-08-27 | メルク シヤープ エンド ドーム リミテツド | ベンゾイミダゾール誘導体 |
JPH07291969A (ja) * | 1994-04-22 | 1995-11-07 | Merck Patent Gmbh | 3−インドリルピペリジン |
JPH08325257A (ja) * | 1995-05-31 | 1996-12-10 | Adir | 新規なピペラジン、ピペリジン及び1,2,5,6−テトラヒドロピリジン化合物、これらの製造方法及びこれらを含む医薬組成物 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1070715A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1242072A1 (en) * | 1999-12-17 | 2002-09-25 | Bristol-Myers Squibb Company | Antipsychotic heterocycle compounds |
EP1242072A4 (en) * | 1999-12-17 | 2004-02-04 | Bristol Myers Squibb Co | ANTIPSYCHOTIC HETEROCYCLIC COMPOUNDS |
EP1598068A1 (en) * | 1999-12-17 | 2005-11-23 | Bristol-Myers Squibb Company | Antipsychotic heterocycle compounds |
US6703383B2 (en) | 2000-09-11 | 2004-03-09 | Sepracor, Inc. | Antipsychotic sulfonamide-heterocycles, and methods of use thereof |
US6872716B2 (en) | 2000-09-11 | 2005-03-29 | Sepracor, Inc. | Antipsychotic sulfonamide-heterocycles, and methods of use thereof |
CN100386323C (zh) * | 2006-02-27 | 2008-05-07 | 南京长澳医药科技有限公司 | 马来酸多潘立酮的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
AU6419698A (en) | 1999-10-11 |
CN1166665C (zh) | 2004-09-15 |
EP1070715A4 (en) | 2002-10-17 |
CN1290263A (zh) | 2001-04-04 |
AU747508B2 (en) | 2002-05-16 |
EP1070715A1 (en) | 2001-01-24 |
US6407121B1 (en) | 2002-06-18 |
CA2324550A1 (en) | 1999-09-23 |
KR20010042001A (ko) | 2001-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999047515A1 (fr) | Derives d'arylpiperidine et utilisation de ceux-ci | |
US10807982B2 (en) | Bromodomain inhibitors | |
US11040966B2 (en) | Benzimidazole-proline derivatives | |
JP6262228B2 (ja) | RORcモジュレーターとしてのアリールスルタム誘導体 | |
CA2888210C (en) | Methylene linked quinolinyl modulators of ror-gamma-t | |
RU2487873C2 (ru) | 5-замещенные индазолы в качестве ингибиторов киназы | |
EP2566477B1 (en) | Amino-quinolines as kinase inhibitors | |
WO2011123609A1 (en) | Imidazolyl-imidazoles as kinase inhibitors | |
US20110178041A1 (en) | Heterocyclic biaryl derivative and pde inhibitor comprising same as active ingredient | |
EA015034B1 (ru) | 2-анилин-4-арилзамещенные тиазольные производные | |
EP3287454A1 (en) | Heterocyclic compound | |
CN105263922B (zh) | 三唑化合物及其作为γ分泌酶调节剂的用途 | |
US6806275B2 (en) | Arylpiperidine derivatives and use thereof | |
JPH1095781A (ja) | アリールピペリジン誘導体 | |
US6291467B1 (en) | Heteroaromatic derivatives | |
JP2018111688A (ja) | 医薬組成物 | |
WO1998012195A1 (fr) | Derives du 2-carbonylthiazole et leur utilisation | |
KR101121662B1 (ko) | 도파민 d3, d4 수용체 길항제인 신규 3-(메톡시메틸)피라졸 유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
BR112019010167A2 (pt) | pirrolopirimidinas como potenciadores de cftr | |
EP1207159A1 (en) | Aromaheterocyclic derivatives as dopamine D4 receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98813917.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 64196/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09646080 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998909760 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2324550 Country of ref document: CA Ref document number: 2324550 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007010329 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1998909760 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007010329 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 64196/98 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998909760 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007010329 Country of ref document: KR |